Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.60 |
| ▸ | OGG1 | O15527 | 1/20 | 0.52 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.50 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | BACE1 | P56817 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7427750 | 0.81 | MAOB (0.69) | KDM4EALDH1A1MAOBRAB9AMEN1 | |
| SCHEMBL17004469 | 0.81 | ALDH1A1 (0.60) | KDM4EALDH1A1NPC1RAB9AMEN1 | |
| SCHEMBL31347402 | 0.81 | KDM4E (0.60) | KDM4EALDH1A1MAPTNPC1RAB9A | |
| SCHEMBL1095318 | 0.81 | KDM4E (0.60) | KDM4EALDH1A1MAPTNPC1RAB9A | |
| SCHEMBL10060679 | 0.80 | KDM4E (0.55) | KDM4EALDH1A1MAOBRAB9AMEN1 | |
| SCHEMBL30065409 | 0.80 | KDM4E (0.55) | KDM4EALDH1A1MAOBRAB9AMEN1 | |
| SCHEMBL285908 | 0.80 | KDM4E (0.55) | KDM4EALDH1A1MAOBNPC1RAB9A | |
| Hydrochloric Acid SCHEMBL10709740 | 0.80 | MAOB (0.68) | KDM4EALDH1A1MAOBRAB9AMEN1 | |
| SCHEMBL23236347 | 0.79 | EGLN1 (0.61) | KDM4EALDH1A1MAOBTSHR | |
| SCHEMBL9180143 | 0.78 | ALDH1A1 (0.56) | KDM4EALDH1A1OGG1P2RX7MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115919859-B | Pharmaceutical composition of heteroaryl derivative and application of pharmaceutical composition in medicine | 四川海思科制药有限公司 | 2024-01-05 | — | — | CN | disclosed |
| US-20230373985-A1 | KINASE MODULATORS AND METHODS OF USE THEREOF | ORIGENIS GMBH (DE) | 2023-11-23 | — | — | US | disclosed |
| CN-115919859-A | Pharmaceutical composition of heteroaryl derivative and application thereof in medicine | 四川海思科制药有限公司 | 2023-04-07 | — | — | CN | disclosed |
| WO-2022011338-A2 | KINASE MODULATORS AND METHODS OF USE THEREOF | ORIGENIS GMBH (DE) | 2022-01-13 | — | — | WO | disclosed |
| WO-2022011337-A1 | KINASE MODULATORS AND METHODS OF USE THEREOF | ORIGENIS GMBH (DE) | 2022-01-13 | — | — | WO | disclosed |
| EP-3459953-B1 | NOVEL 5H-PYRROLO[2,3-D]PYRIMIDIN-6(7H)-ONE DERIVATIVE | TAIHO PHARMACEUTICAL CO LTD (JP) | 2021-06-30 | — | — | EP | disclosed |
| US-10696690-B2 | Imidazo-oxadiazole and imidazo-thiadiazole derivatives | ARES TRADING S.A. (CH) | 2020-06-30 | — | — | US | disclosed |
| US-20190292190-A1 | NOVEL 5H-PYRROLO[2,3-D]PYRIMIDIN-6(7H)-ONE DERIVATIVE | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2019-09-26 | — | — | US | disclosed |
| EP-3459953-A1 | NOVEL 5H-PYRROLO[2,3-D]PYRIMIDIN-6(7H)-ONE DERIVATIVE | Taiho Pharmaceutical Co., Ltd. (JP) | 2019-03-27 | — | — | EP | disclosed |
| US-20180215770-A1 | IMIDAZO-OXADIAZOLE AND IMIDAZO-THIADIAZOLE DERIVATIVES | ARES TRADING SA (CH) | 2018-08-02 | — | — | US | disclosed |
| US-20070185078-A1 | Substituted triazole derivatives as oxytocin antagonists | PFIZER, INC. | 2007-08-09 | — | — | US | disclosed |
| US-20070185078-A1 | Substituted triazole derivatives as oxytocin antagonists | PFIZER, INC. | 2007-08-09 | — | — | US | disclosed |
| EP-1758910-A1 | SUBSTITUTED TRIAZOLE DERIVATIVES AS OXYTOCIN ANTAGONISTS | Pfizer Limited (GB) | 2007-03-07 | — | — | EP | disclosed |
| WO-2006100588-A1 | SUBSTITUTED TRIAZOLE DERIVATIVES AS OXYTOCIN ANTAGONISTS | PFIZER LIMITED (GB) | 2006-09-28 | — | — | WO | disclosed |
| WO-2006100588-A1 | SUBSTITUTED TRIAZOLE DERIVATIVES AS OXYTOCIN ANTAGONISTS | PFIZER LIMITED (GB) | 2006-09-28 | — | — | WO | disclosed |
| WO-2005121152-A1 | SUBSTITUTED TRIAZOLE DERIVATIVES AS OXYTOCIN ANTAGONISTS | PFIZER LIMITED (GB) | 2005-12-22 | — | — | WO | disclosed |
| WO-2005121152-A1 | SUBSTITUTED TRIAZOLE DERIVATIVES AS OXYTOCIN ANTAGONISTS | PFIZER LIMITED (GB) | 2005-12-22 | — | — | WO | disclosed |
| WO-2005028452-A9 | SUBSTITUTED TRIAZOLE DERIVATIVES AS OXYTOCIN ANTAGONISTS | PFIZER LTD (GB) | 2005-07-21 | — | — | WO | disclosed |
| WO-2005028452-A9 | SUBSTITUTED TRIAZOLE DERIVATIVES AS OXYTOCIN ANTAGONISTS | PFIZER LTD (GB) | 2005-07-21 | — | — | WO | disclosed |
| US-20050107382-A1 | e.g. 2-(4-fluoro-2-methylphenyl)-5-(5-methoxymethyl-4-(6-methoxypyridin-3-yl)-4H-[1,2,4]triazol-3-yl)-pyridine; treatment of arousal disorder, orgasmic disorder, sexual pain disorder and premature ejaculation, preterm labor, appetite and feeding disorders, dysmenorrhoea, congestive heart failure, etc. | PFIZER INC. | 2005-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230373985-A1 | KINASE MODULATORS AND METHODS OF USE THEREOF | TYK2, MAPKAPK2, MAP3K20 | KDM4E 688/4885ALDH1A1 4878/4885OGG1 1460/4885 |
| US-20050107382-A1 | e.g. 2-(4-fluoro-2-methylphenyl)-5-(5-methoxymethyl-4-(6-methoxypyridin-3-yl)-4H-[1,2,4]triazol-3-yl)-pyridine; treatment of arousal disorder, orgasmic disorder, sexual pain disorder and premature ejaculation, preterm labor, appetite and feeding disorders, dysmenorrhoea, congestive heart failure, etc. | OXTR, OPRL1, NPY4R | KDM4E 655/4885ALDH1A1 2633/4885OGG1 4829/4885 |
| US-20180215770-A1 | IMIDAZO-OXADIAZOLE AND IMIDAZO-THIADIAZOLE DERIVATIVES | APP, BACE1, PSEN1 | KDM4E 4491/4885ALDH1A1 1206/4885OGG1 3429/4885 |
| US-20070185078-A1 | Substituted triazole derivatives as oxytocin antagonists | OXTR, AVPR2, AVPR1B | KDM4E 4089/4885ALDH1A1 4211/4885OGG1 4371/4885 |
| US-10696690-B2 | Imidazo-oxadiazole and imidazo-thiadiazole derivatives | APP, BACE1, PSEN1 | KDM4E 4491/4885ALDH1A1 1206/4885OGG1 3429/4885 |
| US-20190292190-A1 | NOVEL 5H-PYRROLO[2,3-D]PYRIMIDIN-6(7H)-ONE DERIVATIVE | RPS6KA1, RPS6KA3, MAPK9 | KDM4E 2994/4885ALDH1A1 4446/4885OGG1 1488/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.